Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (220)	6/11/1999 2:20:00 PM
From: Mike McFarland	Respond to of 52153

Great find, that one is a hardcopy now... A fellow on another thread asked what I thought about buying into the health care sector, I responded with my a typical rant on biotech valuation versus pharma PE's. If you posted a follow up to my comments it would probably be appreciated over there-- here is the url Message 10083679 Have appreciated your recent comments on sideways mergers of third and fourth tier...in fact, I am having a tall glass of Kool Aid as we speak...

To: Biomaven who wrote (220)	6/11/1999 9:45:00 PM
From: John Dwyer	Read Replies (2) \| Respond to of 52153

Peter... great article! Thanks. I'll make a hardcopy of that tomorrow and try to look over it more closely. Some of you may know I have been testing the job market in recent weeks... I can't be a wandering postdoc forever! I have found to my surprise that there are a whole bunch of very interesting private biotechs that have good platforms and stuff in the pipe. It appears that if the malaise for biotech ever lifts there will be not be a paucity of interesting biotech IPO's. Some interesting examples include Rigel, Novalon, Structural Bioinformatics, Angstrom... very cool!! John